bp

BP is a rare class enhancer of proteasomal activation in the absence of a heat shock response.

BP14979 is a dopamine D3 receptor agonist that can be used to study neurological disorders.

BP 897 is a potent and selective agonist of dopamine D3 receptor and it is a weak dopamine D2 receptor antagonist, with Kis of 0.92 nM and 61 nM for D3 and D2 receptors. Which shows low affinities at D1 and D4 receptors (Kis, 3 and 0.3 μM, respectively).

MGB-BP-3 is a synthetic antibiotic with bactericidal activity that inhibits bacterial DNA replication and can be used to study recurrent C. difficile infections.

BP-198 is a MproPROTAC degrader that enhances the ubiquitination and degradation of Mpro. It exhibits antiviral activity against SARS-CoV-2 with an IC50 of 11.8 μM and demonstrates increased efficacy against drug-resistant viruses.

163-bp3 is an effective photoaffinity probe and can be used as a target γ Secretory enzyme.

BP-1-102 is an orally active, effective, and specific STAT3 inhibitor that binds Stat3 (Kd: 504 nM), blocks Stat3-phosphotyrosine (pTyr) peptide interactions and Stat3 activation (4-6.8 μM), and selectively inhibits the migration, survival, growth, and invasion of Stat3-dependent tumor cells. The BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of [c-Myc, Bcl-xL, Cyclin D1, Survivin, and VEGF].

BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia.

SNU-BP is an agonist of PPAR-gamma, inhibiting lipopolysaccharide (LPS)-induced NO production and pro-inflammatory cytokines. SNU-BP potentiates interleukin-4-induced arginase-1 expression, and promotes microglial polarization toward an M2 anti-inflammatory phenotype.

BP-1-108 is a potent and selective STAT5 inhibitor.

BP-M345 (compound 5) serves as a powerful antiproliferative agent that selectively targets cancer cells while demonstrating minimal toxicity to non-tumor cells. It effectively inhibits cancer cell proliferation, achieving a GI 50 value between 0.17 to 0.45 μM [1].

BP 897 (2-Naphthalenecarboxamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-) is a potent and selective dopamine D3 receptor agonist, and a weak dopamine D2 receptor antagonist, with Kis of 0.92 nM and 61 nM for D3 and D2 receptors, and shows low affinities at D1 and D4 receptors (Kis, 3 and 0.3 μM, respectively).

BP lipid 700 is classified as an ionizable cationic lipid.

Cys-αvβ6-BP is a peptide that binds to αvβ6 and is terminated with cysteine.

Cys-αvβ6-BP TFA is a cysteine-terminated peptide that binds to αvβ6.

αvβ6-BP is a selective αvβ6-binding peptide, useful for research in molecular imaging.

αvβ6-BP TFA is a selective αvβ6-binding peptide used for molecular imaging research.

plCSA-BP is a placental CSA-binding peptide that specifically binds to trophoblastic cells without interacting with other cell types in the placenta or with CSA-expressing cells in other tissues. It can direct nanoparticles to deliver payloads, such as Indocyanine green (ICG) and Methotrexate (MTX), for targeted placental drug delivery, highlighting its potential in placenta-specific drug delivery research.

Potassium chloride is an inorganic salt that meets the analytical specifications of Ph. Eur., BP, USP, FCC, and E508, with an aluminum content of ≤0.0001%. It is suitable for use in buffer solution preparation.

4BP-TQS is an allosteric agonist of α7 nAChRs.

BP13944 is used as a potential dengue virus NS2B/NS3 protease inhibitor.

G3BP1/2-Targeting ligand-1 is a ligand for G3BP1/2 and can be utilized as a targeting ligand in the synthesis of the G3BP1/2 PROTAC degrader PT-129.

3BP-3580 is an inhibitor of fibroblast activation protein (FAP) with a pIC50 value of 8.6, utilized in cancer research.

IGF2BP3-IN-1 is an inhibitor of IGF2BP3 (an RNA-binding protein) with an IC50 greater than 50 μM, suitable for cancer research.